Cargando…
476. Gilead Sciences’ Commitment to the COVID-19 Pandemic
BACKGROUND: COVID-19 has spread rapidly: from the first case in Dec 2019, the declaration of a global pandemic in Mar 2020, to Jun 18, 2020 with >8 M confirmed cases and >400,000 deaths worldwide. Throughout this rapid spread, Gilead has focused on contributing antiviral expertise and resource...
Autores principales: | Lee, EunYoung, Osinusi, Anu, Chokkalingam, Anand, Brainard, Diana M, Tran, Tram, Dau, Lauren, Ferrinho, Diogo, Wang, ChenYu, Juneja, Kavita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777090/ http://dx.doi.org/10.1093/ofid/ofaa439.669 |
Ejemplares similares
-
Paying Attention to Beauty (Gilead)
por: Hibbs, Stephen, et al.
Publicado: (2021) -
Does IHU-Méditerranée Infection influence Gilead Sciences' stock price?
por: Chabrière, E.
Publicado: (2020) -
Health Tract, No. 198: Balm of Gilead
Publicado: (1865) -
An Accidental Proving of Balm of Gilead Buds
por: Stilson, W. C.
Publicado: (1891) -
Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences
por: Roussel, Y., et al.
Publicado: (2020)